Seres Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 19.59M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI...